[1-[(4-fluoroanilino)methyl]-2-azabicyclo[3.1.1]heptan-2-yl]-(2-methyl-5-pyrazin-2-yl-1,3-thiazol-4-yl)methanone
C22H22FN5OS — CID 142567180
Data last refreshed: (MolForge compound catalog, from PubChem)
About [1-[(4-fluoroanilino)methyl]-2-azabicyclo[3.1.1]heptan-2-yl]-(2-methyl-5-pyrazin-2-yl-1,3-thiazol-4-yl)methanone
[1-[(4-fluoroanilino)methyl]-2-azabicyclo[3.1.1]heptan-2-yl]-(2-methyl-5-pyrazin-2-yl-1,3-thiazol-4-yl)methanone (PubChem CID 142567180) has the molecular formula C22H22FN5OS and a molecular weight of 423.52 g/mol. Its IUPAC name is [1-[(4-fluoroanilino)methyl]-2-azabicyclo[3.1.1]heptan-2-yl]-(2-methyl-5-pyrazin-2-yl-1,3-thiazol-4-yl)methanone.
Molecular Properties
| Compound Name | [1-[(4-fluoroanilino)methyl]-2-azabicyclo[3.1.1]heptan-2-yl]-(2-methyl-5-pyrazin-2-yl-1,3-thiazol-4-yl)methanone |
|---|---|
| PubChem CID | 142567180 |
| Molecular Formula | C22H22FN5OS |
| Molecular Weight | 423.52 g/mol |
| Exact Mass | 423.15 |
| IUPAC Name | [1-[(4-fluoroanilino)methyl]-2-azabicyclo[3.1.1]heptan-2-yl]-(2-methyl-5-pyrazin-2-yl-1,3-thiazol-4-yl)methanone |
| SMILES | Cc1nc(C(=O)N2CCC3CC2(CNc2ccc(F)cc2)C3)c(-c2cnccn2)s1 |
| InChI | InChI=1S/C22H22FN5OS/c1-14-27-19(20(30-14)18-12-24-7-8-25-18)21(29)28-9-6-15-10-22(28,11-15)13-26-17-4-2-16(23)3-5-17/h2-5,7-8,12,15,26H,6,9-11,13H2,1H3 |
| InChIKey | UZOWFGABYOQSBB-UHFFFAOYSA-N |
| XLogP | 4.15 |
| TPSA | 71.01 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 423.52 |
| LogP ≤ 5 | 4.15 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 142567180 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.